Maze Therapeutics, Inc. (MAZE) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-87.4%

$3.82

vs $30.37 price

Levered DCF

$3.86

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

11.54

Safe zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022
P/E	-13.58×	205.01×	-6.95×	-6.07×
P/B	5.02×	3.55×	69.45×	6.88×
P/S	0×	4.17×	0×	0×
EV / EBITDA	-12.54×	9.32×	-7.46×	-5.67×
Gross margin	0.0%	100.0%	0.0%	0.0%
Operating margin	0.0%	34.4%	0.0%	0.0%
Net margin	0.0%	31.2%	0.0%	0.0%
Current ratio	15.5×	9.76×	2.09×	5.11×
Debt / equity	0.07×	0.14×	4.94×	0.32×
Interest coverage	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022
Return on equity	-36.9%	26.5%	-998.8%	-113.3%
Return on invested capital	-37.7%	25.1%	-165.1%	-83.2%
Return on assets	-33.0%	21.7%	-140.4%	-76.6%
Free cash flow yield	-6.3%	10.7%	-12.5%	-14.5%
Earnings yield	-7.4%	7.5%	-14.4%	-16.5%
Enterprise value	$1.6B	$528.4M	$718.7M	$630.4M
Net debt / EBITDA	1.29×	-3×	-0.21×	0.61×
Cash conversion cycle (days)	-272	0	0	0